Gilead Sciences, Inc. is poised to present its latest research findings at the European Association for the Study of the Liver (EASL) Congress, taking place from June 5-8, 2024, in Milan, Italy. This event will showcase over 25 abstracts, underscoring significant progress in the treatment of liver diseases.
Key highlights include interim results from the two-year ASSURE study, which evaluates the long-term efficacy and safety of the investigational drug seladelpar for primary biliary cholangitis (PBC). Additionally, a comprehensive analysis will demonstrate the effectiveness of tenofovir-based antiviral therapy in reducing the incidence of primary liver cancer among patients with chronic hepatitis B (HBV). The final results from the Phase 2b MYR204 study will also be presented, assessing the efficacy of Hepcludex® (bulevirtide) in combination with pegylated interferon alfa-2a for chronic hepatitis delta virus (HDV) patients. A late-breaking presentation will focus on the MYR301 Phase 3 study of bulevirtide as a standalone treatment.
Dr. Frank Duff, Senior Vice President at Gilead Sciences, highlighted the company's commitment to transformative science and improving the lives of individuals with liver disease. He stated, "Our research encompasses everything from initial awareness and education to ongoing management, addressing unmet needs at every stage of a patient's journey."
Efforts to Combat Viral Hepatitis
In support of the World Health Organization's objective to eliminate viral hepatitis as a public health threat by 2030, Gilead will present real-world data on hepatitis C (HCV) and launch a national awareness initiative in Italy. The program, "Epatite C Mettiamoci un Punto," aims to enhance disease awareness and promote testing through EASL's "Love Your Liver" campaign.
Progress in Primary Biliary Cholangitis (PBC)
New insights into the long-term efficacy and safety of seladelpar for PBC treatment will be unveiled at EASL. The interim results from the ASSURE study focus on patients with inadequate response to first-line treatment, evaluating biochemical response and pruritus in PBC, a rare liver disease predominantly affecting women over 40.
Insights into Hepatitis Delta Virus (HDV)
Gilead will present 13 abstracts on HDV, including findings from the MYR204 and MYR301 studies. These studies evaluate the efficacy and safety of bulevirtide, highlighting its potential as a treatment for HDV, the most severe form of viral hepatitis. A sub-analysis will examine intrahepatic virological outcomes, while a pooled analysis will discuss the impact of nucleos(t)ide analogues in conjunction with bulevirtide.
Gilead's Dedication to Liver Disease Research
For decades, Gilead has been a leader in liver disease research, transforming hepatitis C into a curable condition for millions. The company's focus extends to hepatitis B and D, with ongoing efforts to develop advanced treatments for PBC. Through scientific innovation and strategic partnerships, Gilead aims to create healthier futures for those living with liver disease.
Gilead Sciences, Inc. is a biopharmaceutical leader committed to advancing innovative medicines for life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. With operations in over 35 countries, Gilead is headquartered in Foster City, California.